Archive

Tag: Anticoagulation

Lower GI bleeding CTA decision graphic showing a CT scanner with the text: Who needs a CTA? Unstable, active bleeding, bleeding within 4 hours.

Clinical Conundrum — Lower GI Bleeding: Who Needs a CTA?

CTA is the preferred initial test for unstable patients with suspected active lower GI bleeding, but it should not be routinely ordered in all cases. Here’s how to decide who actually benefits.

Read More
Abdominal and Gastrointestinal

Is Abelacimab the Next Step in AF Anticoagulation? Early Signals and Remaining Questions

Antithrombotic therapy is a cornerstone in the treatment of atrial fibrillation (AFib), though it carries a significant risk of bleeding. While Vitamin K antagonists (VKAs), the oldest anticoagulants, were largely supplanted by direct oral anticoagulants (DOACs) following trials like ARISTOTLE ...

Read More
Cardiovascular

VTE Recurrence in Subsegmental PE: What’s the Risk?

Background: The overall mortality and case-fatality rate for pulmonary embolism (PE) are decreasing. Yet reporting is increasing, suggesting we are overdiagnosing PE. Furthermore, management with anticoagulation is not entirely benign and places a potential risk of bleeding upon the patient. ...

Read More
Thoracic and Respiratory

The INSPIRATION Trial: Intermediate Dose Anticoagulation in Critically Ill Patients with COVID-19

Background: COVID-19 infection increases the risk of thrombosis due to multiple factors.(Rico-Mesa, 2020). Over the last 2 years, researchers have published 12 RCTs investigating various anticoagulation strategies among patients diagnosed with COVID-19 in multiple clinical settings. To date, only a multiplatform ...

Read More
CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory

The MICHELLE Trial: Anticoagulation Post-Discharge in Patients Hospitalized Secondary to COVID-19

Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin ...

Read More
CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory
Showing Slide 1 of 6

Sponsored